Weyhenmeyer B, Murphy A C, Prehn J H M, Murphy B M
Centre for Systems Medicine, Department of Physiology and Medical Physics, St. Stephen's Green, Dublin 2, Ireland.
Exp Oncol. 2012 Oct;34(3):192-9.
Most cells express a variety of both anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction within this family dictates whether a cell survives or dies. The dysregulation of the anti-anti-apoptotic Bcl-2 family members is one of the defining features of cancer cells in comparison to normal cells, and significantly contributes to the resistance of cancer cells to current treatment modalities. This anti-apoptotic subfamily of proteins is now a major target in the development of new methods to improve treatment outcomes for cancer patients. Several drugs directed at inhibiting Bcl-2 and related anti-apoptotic proteins have been developed with some showing considerable promise in the clinic. This Review presents the current knowledge of the role of the anti-apoptotic Bcl-2 family in cancer cells, as well as current and future perspectives on targeting this subfamily of proteins for therapeutic intervention in human malignancies. This article is part of a Special Issue entitled "Apoptosis: Four Decades Later".
大多数细胞都表达多种抗凋亡和促凋亡的Bcl-2蛋白，该蛋白家族内的相互作用决定了细胞的生死存亡。与正常细胞相比，抗凋亡Bcl-2家族成员的失调是癌细胞的一个决定性特征，并显著导致癌细胞对当前治疗方式产生抗性。现在，这个抗凋亡蛋白亚家族已成为开发改善癌症患者治疗效果新方法的主要靶点。已经研发出几种针对抑制Bcl-2及相关抗凋亡蛋白的药物，其中一些在临床上显示出了相当大的前景。本综述介绍了抗凋亡Bcl-2家族在癌细胞中的作用的当前知识，以及针对该蛋白亚家族进行人类恶性肿瘤治疗干预的当前和未来观点。本文是名为“细胞凋亡：四十年后”的特刊的一部分。
